The ratings of five Pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, Flamel Technologies (NASDAQ:FLML) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Flamel Technologies develops polymer technologies for applications such as drug delivery, biomaterials, and agrochemicals. In Portfolio Grader’s specific subcategories of Earnings Revisions, Equity, and Sales Growth, FLML also gets an F. The stock price has dropped 7.1% over the past month, worse than the 4.2% decrease the Nasdaq has seen over the same period of time. For a full analysis of FLML stock, visit Portfolio Grader.
Sagent Pharmaceuticals (NASDAQ:SGNT) ratings are on the decline this week as the company earns a F (“strong sell”). Last week, it received a D (“sell”). Sagent Holding Co is an injectable pharmaceutical company that develops and sources products which they sell primarily in the United States. The stock gets F’s in Earnings Revisions and Equity. For more information, get Portfolio Grader’s complete analysis of SGNT stock.
Dr. Reddy’s Laboratories‘ (NYSE:RDY) rating weakens this week, dropping to a D versus last week’s C. Dr. Reddy Laboratories is a global company that produces and markets active pharmaceutical ingredients, intermediates, finished dosage forms, and biologic products. To get an in-depth look at RDY, get Portfolio Grader’s complete analysis of RDY stock.
Slipping from a C to a D rating, Warner Chilcott (NASDAQ:WCRX) takes a hit this week. Warner Chilcott engages in the development, manufacture, and promotion of branded pharmaceutical products focusing on the womens healthcare, gastroenterology, dermatology, and urology markets in North America and western Europe. Share prices fell 9.5% over the past month. For more information, get Portfolio Grader’s complete analysis of WCRX stock.
Horizon Pharma Inc. (NASDAQ:HZNP) gets weaker ratings this week as last week’s C drops to a D. Horizon Pharma is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The stock gets F’s in Equity and Cash Flow. Wall Street appears to agree with the stock downgrade, with share prices dropping 21% over the past month. For a full analysis of HZNP stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.